Statement Of Cash Flows [Abstract]

Medistim - Filing #5830287

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
103 832 NOK
103 823 NOK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories
15 130 NOK
31 058 NOK
Adjustments for decrease (increase) in trade accounts receivable
5 323 NOK
27 354 NOK
Adjustments for increase (decrease) in trade accounts payable
1 951 NOK
613,000 NOK
Adjustments for depreciation and amortisation expense
24 510 NOK
23 657 NOK
Adjustments for share-based payments
1 068 NOK
6 009 NOK
Cash flows from (used in) operating activities
143 104 NOK
119 198 NOK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
6 068 NOK
16 399 NOK
Cash flows from (used in) investing activities
24 693 NOK
29 726 NOK
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities
9 115 NOK
8 712 NOK
Dividends paid, classified as financing activities
82 414 NOK
82 180 NOK
Cash flows from (used in) financing activities
91 529 NOK
90 892 NOK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
1 544 NOK
2 651 NOK
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
25 338 NOK
1 231 NOK
Cash and cash equivalents
179 210 NOK
153 872 NOK
152 641 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.